Compare MPB & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPB | DRUG |
|---|---|---|
| Founded | 1868 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 856.0M | 707.1M |
| IPO Year | 1996 | 2020 |
| Metric | MPB | DRUG |
|---|---|---|
| Price | $32.63 | $87.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $37.00 | ★ $129.25 |
| AVG Volume (30 Days) | 107.3K | ★ 208.4K |
| Earning Date | 04-21-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.95 | N/A |
| Revenue Next Year | $9.45 | N/A |
| P/E Ratio | $90.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.83 | $23.18 |
| 52 Week High | $35.22 | $123.75 |
| Indicator | MPB | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 50.68 | 56.62 |
| Support Level | $30.66 | $70.35 |
| Resistance Level | $34.88 | $91.69 |
| Average True Range (ATR) | 0.77 | 4.92 |
| MACD | 0.10 | 0.72 |
| Stochastic Oscillator | 78.30 | 78.51 |
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.